Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Junctional epidermolysis bullosa, non-Herlitz (JEB-nH) is a subtype of junctional epidermolysis bullosa (JEB) characterized by the presence of skin and mucosal blistering, nail dystrophy or nail absence and enamel hypoplasia.
Features include always present findings: Carious teeth, Patchy alopecia, Abnormal blistering of the skin, and Enamel hypoplasia and others. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 7 | Patchy alopecia, Fragile nails, Abnormal blistering of the skin |
Arms and legs | 1 | Camptodactyly of finger |
Junctional epidermolysis bullosa (JEB) is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Broad classification of JEB includes JEB generalized severe and JEB generalized intermediate and is based on severity and survival past the first years of life . JEB generalized severe (previously called JEB Herlitz). Severe blistering is present at birth or becomes apparent in the neonatal period and may lead to large regions of affected skin with significant granulation tissue. Granulation tissue characteristically appears around the nose, mouth, ears, and tips of the fingers and toes as well as in areas subject to friction such as the buttocks and the back of the head. Persistent plaques on the face can be challenging to treat.
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
LAMB3 encodes laminin subunit beta 3 (1,172 aa). Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ext... Highest expression in Skin Sun Exposed Lower leg (57.8 TPM) and Skin Not Sun Exposed Suprapubic (54.8 TPM).
Junctional epidermolysis bullosa, non-Herlitz type is associated with mutations in the LAMB3 gene on chromosome 1.
LAMB3 is classified as a druggable target (Druggable Genome category) with score 1.7.
JEB generalized severe is the result of inactivating pathogenic variants on both alleles, which result in little or no functional protein . For frameshift variants, the severity may be related to where the stop codon is located and whether any functional (although truncated) protein is formed; the presence of some functional protein appears to be the most important factor in mitigating disease severity . JEB generalized intermediate generally results from amino acid substitutions and splice-junction variants, although it is difficult to generalize because of the wide phenotypic variability and range of allelic variants that have been identified .
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Junctional epidermolysis bullosa (JEB) should be suspected in individuals who have fragility of the skin with:
Blistering with little or no trauma. Blistering may be mild or severe; however, blisters generally heal with no significant scarring.
Significant oral and mucous membrane involvement
Note: Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers and toes, and internally in and around the upper airway and the trachea .
The diagnosis of JEB is established in a proband with one or both of the following:
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Epidermolysis bullosa (EB). According to the 2014 classification system, the four major types of EB, caused by pathogenic variants in 18 different genes, are EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome (KS) . Classification into major type is based on the location of blistering in relation to the dermal-epidermal junction of skin. Subtypes are predominantly determined by clinical features and supported by molecular diagnosis. The four major types of EB share easy fragility of the skin (and mucosa in many cases), manifested by blistering with little or no trauma.
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Genetic testing for LAMB3 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for junctional epidermolysis bullosa, non-Herlitz type. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with junctional epidermolysis bullosa (JEB), the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Evaluation of the sites of blister formation, including mouth, esophagus, and airway in a child with progressive hoarseness or stridor
Direct examination of the airway by an experienced otolaryngologist with appropriately small and lubricated instruments to determine the extent of airway compromise so that decisions regarding tracheostomy can be discussed with the family
Evaluation for gastroesophageal reflux disease, which may cause additional trauma to the upper airway
Evaluation for existing osteopenia through skeletal radiographs or DXA (dual-energy x-ray absorptiometry) scan
Evaluation for cardiomyopathy by clinical evaluation and/or echocardiogram [Fine et all 2008]
Measurements of hemoglobin and electrolytes to evaluate for anemia and electrolyte imbalance
Skin bacterial cultures and blood cultures in clinically ill infants to decide appropriate antibiotic treatment
Consultation with a clinical geneticist and/or genetic counselor
Note: Clinical decision making in children who manifest sign and symptoms of severe JEB with a very poor prognosis has been debated and remains difficult .
Skin. The skin needs to be protected from shearing forces and caretakers need to learn how to handl...
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Most persons with JEB cannot use ordinary medical tape or Band-Aids®. Silicone-based products provide a good substitute for tape. Poorly fitting or coarse-textured clothing and footwear can cause trauma. Activities such as hiking, mountain biking, and contact sports traumatize the skin; affected individuals who are determined to participate in such activities should be encouraged to find creative ways to protect their skin.
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Several approaches to gene therapy for JEB, focused on retroviral modification of in vitro epidermal cells, have been proposed . One successful clinical trial has been conducted using transplantation of sheets of genetically modified epidermal stem cells in one affected individual with biallelic LAMB3 pathogenic variants . Animal models include intra-amniotic prenatal laminin 332 delivery in mouse and a spontaneous form of JEB in dog . The use of a variety of viral vectors, including AAV , lentivirus , and retroviruses , is being explored to correct the pathogenic variants in cells cultured from individuals with JEB in preparation for transplantation back onto severely affected sites, and shows promise for future clinical trials.
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
5 trials found
Surveillance includes the following:
Annual complete blood counts and measurement of serum iron concentration to screen for iron-deficiency anemia
Annual measurement of serum zinc concentration to screen for zinc deficiency
Annual measurement of serum vitamin D
Screening with bone mineral density scanning may detect early osteopenia and/or osteoporosis. No guidelines have been established regarding the age at which this should be initiated.
Screening for dilated cardiomyopathy with periodic echocardiograms
Skin examination starting in the second decade of life for wounds that do not heal, have exuberant scar tissue, or otherwise look abnormal to screen for squamous cell carcinoma. Frequent biopsies of suspicious lesions followed by local excision may be necessary.
Source: GeneReviews — "Junctional Epidermolysis Bullosa"
Phenotype severity distribution: 5 always present features.
5 clinical trials registered, 4 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 1 PHASE3, 1 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06594393](https://clinicaltrials.gov/study/NCT06594393) | A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | PHASE2 | Xinnate AB | RECRUITING |
[NCT06917690](https://clinicaltrials.gov/study/NCT06917690) | A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa | PHASE3 | Chiesi Farmaceutici S.p.A. | RECRUITING |
[NCT06713434](https://clinicaltrials.gov/study/NCT06713434) | Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa | PHASE1 | Fundación DEBRA Chile, Niños Piel de Cristal | ACTIVE_NOT_RECRUITING |
[NCT06423573](https://clinicaltrials.gov/study/NCT06423573) | A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez | — | Amryt Pharma | RECRUITING |
[NCT03526159](https://clinicaltrials.gov/study/NCT03526159) | Gentamicin for Junctional Epidermolysis Bullosa | PHASE1 | University of Southern California | RECRUITING |
85 publications have been identified in PubMed for junctional epidermolysis bullosa, non-Herlitz type. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 29 | 35% |
Research summaries | 14 | 17% |
Disease patterns and progression | 14 | 17% |
Laboratory research | 13 | 16% |
New treatment approaches | 8 | 10% |
Clinical study results | 3 |
Hanrahan GB (2026). [PMID: 41723962](https://pubmed.ncbi.nlm.nih.gov/41723962/). *Pediatric dermatology*. [Review / Meta-Analysis]
McClatchy J (2026). [PMID: 41737335](https://pubmed.ncbi.nlm.nih.gov/41737335/). *Case reports in dermatological medicine*. [Epidemiology / Natural History]
Feinstein JA (2026). [PMID: 41735025](https://pubmed.ncbi.nlm.nih.gov/41735025/). *Pediatric dermatology*. [Review / Meta-Analysis]
Hierl M (2026). [PMID: 41174881](https://pubmed.ncbi.nlm.nih.gov/41174881/). *Molecular therapy : the journal of the American Society of Gene Therapy*. [Gene Therapy / Novel Therapeutics]
Kazemizadeh A (2026). [PMID: 41500227](https://pubmed.ncbi.nlm.nih.gov/41500227/). *Molecular therapy : the journal of the American Society of Gene Therapy*. [Basic Science / Preclinical]
Xu Q (2026). [PMID: 41476816](https://pubmed.ncbi.nlm.nih.gov/41476816/). *Clinical case reports*. [Gene Therapy / Novel Therapeutics]
Feng X (2026). [PMID: 41675682](https://pubmed.ncbi.nlm.nih.gov/41675682/). *Molecular syndromology*. [Basic Science / Preclinical]
Alsughayer L (2026). [PMID: 41592790](https://pubmed.ncbi.nlm.nih.gov/41592790/). *Ear, nose, & throat journal*. [Case Report / Case Series]
Jouen F (2026). [PMID: 41793217](https://pubmed.ncbi.nlm.nih.gov/41793217/). *Journal of the European Academy of Dermatology and Venereology : JEADV*. [Basic Science / Preclinical]
Tete PI (2026). [PMID: 41728083](https://pubmed.ncbi.nlm.nih.gov/41728083/). *Case reports in pediatrics*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 4:10 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Other research | 2 | 2% |